| Previous Close | 11.87 |
| Open | 11.87 |
| Bid | 11.20 x 100 |
| Ask | 15.79 x 100 |
| Day's Range | 11.49 - 11.93 |
| 52 Week Range | 9.45 - 23.44 |
| Volume | 8,967,185 |
| Avg. Volume | 4,513,079 |
| Market Cap | 1.91B |
| Beta | 1.14 |
| PE Ratio (TTM) | -8.87 |
| EPS (TTM) | -1.32 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.91 |
- GlobeNewswire•10 hours ago
Horizon Pharma plc Completes Sale of European Marketing Rights for PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin nebuliser solution) in Europe, Middle East and Africa (EMEA) Regions to Chiesi Farmaceutici S.p.A.
DUBLIN, Ireland, June 23, 2017-- Horizon Pharma plc, a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible ...
- GlobeNewswire•3 days ago
Horizon Pharma plc Partners with Global Genes® to Unite the Rare Disease Community at the Biotechnology Innovation Organization (BIO) International Convention
DUBLIN, Ireland, June 20, 2017-- Horizon Pharma plc, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible ...
- Zacks•3 days ago
Horizon Pharma Gets Health Canada Approval for Procysbi
Horizon Pharma plc (HZNP), announced that it has received approval in Canada for Procysbi (cysteamine delayed-release capsules) for the treatment of nephropathic cystinosis in adults and children of 2 years old and more.
